ALZ Share Price Performance
SEK 1.03
-0.27 (-20.68%)
98.8% undervalued intrinsic discount
SEK 85.00
Fair Value
Price SEK 1.03
steffen_4h13a SEK 85.00
Fair ValueSEK 85.00
Share Pricen/a
New Narrative • Jul 08
Alzinova AB (publ) Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
ALZ Community Narratives
ST
Fair Value
·Fair Value SEK 85 98.8% undervalued intrinsic discount
Fair value 7.1B Sek
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Fair value 7.1B Sek
A small Alzheimer’s drug developer could get a fresh look as it heads toward a key mid-stage study and presents at a major research meeting. The big question is whether early safety and immune signals for its lead program can translate into partner interest and a step up in market attention.Read more
ST
SEK 85
98.8% undervalued intrinsic discount
Fair Value
Profit Margin
18.49%
Future PE
25.6x
Price in 2029
SEK 99.45
Trending Discussion
No trending discussion available.
Recently Updated Narratives
ST
Fair value 7.1B Sek
Fair Value: SEK 85 98.8% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Alzinova AB (publ) Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 20, 2026
- -0.13
- 100.00%
- -103.58%
- 0.5%
About ALZ
- Founded
- 2011
- Employees
- 7
- CEO
- WebsiteView website
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. The company’s lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alzheimer’s disease that is in phase 1 clinical study. It has a research collaboration with Amsterdam University Medical Center to develop a blood based test that measures naturally occurring antibodies against toxic amyloid ß oligomers. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden.
